Imatinib Mesylate
31 NDCs across 14 manufacturers|28 Generic,3 Brand
Imatinib Mesylate is used to treat blast crisis, dermatofibrosarcoma, gastrointestinal neoplasms, hypereosinophilic syndrome, lymphoid leukemia and myeloid leukemia, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on May 10, 2001, and the first generic was approved Dec 3, 2015. FDA's Orange Book lists 26 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $219 million on Imatinib Mesylate across 130,000 claims for 17,000 beneficiaries.
Imatinib Mesylate is available as 31 NDCs from 14 manufacturers (28 generic, 3 brand), with NADAC prices from $0.49 to $328.03 per EA — the most expensive product costs about 668× the cheapest. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
31
28G / 3B
Manufacturers
14
competing in market
Price Spread
$0.49 – $328.03
per EA
7d Activity
avg -2.1% WoW · of 31 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
BluePoint Laboratories manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Kinase Inhibitor class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
14 manufacturers producing IMATINIB MESYLATE(4 pricing outliers)
Frequently Asked Questions
What is Imatinib Mesylate used to treat?
Imatinib Mesylate is used to treat blast crisis, dermatofibrosarcoma, gastrointestinal neoplasms, hypereosinophilic syndrome, lymphoid leukemia and myeloid leukemia, per the National Library of Medicine's MED-RT classification.
When did Imatinib Mesylate become available as a generic?
FDA approved the first generic Imatinib Mesylate (ANDA) on Dec 3, 2015. The Orange Book currently lists 26 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Imatinib Mesylate?
In 2024, Medicare Part D spent $219 million on Imatinib Mesylate across 130,000 claims for 17,000 beneficiaries.
How many Imatinib Mesylate products are on the market?
The Imatinib Mesylate drug market contains 31 NDCs from 14 manufacturers — 28 generic and 3 brand products.
What is the price range for Imatinib Mesylate?
NADAC reference prices for Imatinib Mesylate range from $0.4912 to $328.0342 per EA — the most expensive product costs about 668× the cheapest.
Is generic Imatinib Mesylate cheaper than brand?
The average generic NADAC for Imatinib Mesylate is $1.8274 per EA, versus $248.9627 for brand-labeled products — brand versions average about 136× the generic price.
Which manufacturers make Imatinib Mesylate?
14 manufacturers list Imatinib Mesylate in NADAC. Ranked by number of NDCs, the largest are BluePoint Laboratories (4), Novartis Pharmaceuticals Corporation (3), Ascend Laboratories, LLC (2), Archis Pharma LLC (2), Sun Pharmaceutical Industries Inc. (2).
How has the price of Imatinib Mesylate changed recently?
Over the past 7 days, 9 Imatinib Mesylate NDCs rose and 8 fell, with a market-wide average change of -2.1%.